| Segment | Revenue | Share |
|---|---|---|
Eliquis | $14.44B | 30.0% |
Opdivo | $10.05B | 20.9% |
Orencia | $3.71B | 7.7% |
Revlimid | $2.95B | 6.1% |
Yervoy | $2.90B | 6.0% |
Pomalyst/Imnovid | $2.73B | 5.7% |
Reblozyl | $2.33B | 4.8% |
Other Growth Brands | $1.92B | 4.0% |
Breyanzi | $1.36B | 2.8% |
Opdualag | $1.19B | 2.5% |
Camzyos | $1.07B | 2.2% |
Other Legacy Brands | $798.0M | 1.7% |
Zeposia | $577.0M | 1.2% |
Sprycel | $493.0M | 1.0% |
Abecma | $427.0M | 0.9% |
Abraxane | $368.0M | 0.8% |
Sotyktu | $291.0M | 0.6% |
Opdivo Ovantig | $238.0M | 0.5% |
Krazati | $205.0M | 0.4% |
Cobenfy | $155.0M | 0.3% |
Other | $0 | 0.0% |
| Segment | Revenue | Share |
|---|---|---|
UNITED STATES | $33.28B | 96.8% |
Other Region | $1.09B | 3.2% |
Other | $0 | 0.0% |